Cellectar Biosciences, Inc. received a notice from Nasdaq stating that it must maintain a minimum of $2,500,000 in stockholders equity for continued listing, but the notice does not immediately impact the listing of the company's stock. The company has 45 days to submit a plan to regain compliance, and if accepted, may be granted an extension period of up to 180 days to regain compliance.